Jump to: navigation, search

Interferon For Treatment of Melanoma

3,706 bytes added, 09:05, 24 February 2011
/* Global Revenue Data Of products */
==Biosimilars Of Interferons==
Biosimilar interferons are the major drug class in the recombinant non-glycosylated proteins market due to their extensive use in the treatment of various genetic and environmental disorders. The overall biosimilar market for interferons is categorized into the submarkets for alpha, beta, and gamma interferons, all of which are used extensively in the treatment of various conditions such as lymphoma, hairy cell leukemia, and multiple sclerosis.
While the interferon market growth may be inhibited by the side effects of each of its three drug categories, the market presents many opportunities to new entrants as only a few players currently operate in this relatively unfragmented market.
The global recombinant interferon market stood at $75.3 million in 2008 and is expected to reach $3.9 billion by 2014 at a CAGR of 82.9% from 2009 to 2014. The American biosimilar interferons market is expected to attain a market worth $1.5 billion by 2014 at a CAGR of 91.5%.[ Biosimilars ; Global Market]
{|border="2" cellspacing="0" cellpadding="4" width="100%"
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''S.No'''</center>
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''Product'''</center>
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''Global market For Biosimilars'''</center>
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''1'''</center>
| style="padding:0.079cm;"| <center>Interferon Alfa</center>
| style="padding:0.079cm;"| <center>The global market for biosimilar interferon Alfa was $36.7 million in 2008 and is expected to reach $1.5 billion in 2014 at a CAGR of 76.5% from 2009 to 2014. While Asian market for biosimilar Alfa interferons commanded the highest share in 2008 with $17.5 million, the American market is expected to have the highest CAGR of 88.3% from 2009 to 2014.The world's top two branded Interferon products generated sales of $1,510 million and $910 million each in 2008. The blockbuster sales of innovative Interferon Alfa products thus present encouragement for biosimilar Interferon Alfa manufacturers[ data].</center>
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''2'''</center>
| style="padding:0.079cm;"| <center>Interferon beta</center>
| style="padding:0.079cm;"| <center>The global biosimilar interferon beta-1a market is estimated to grow from $36.3 million in 2008 to $2.2 billion by 2014 at a CAGR of 87.8% from 2009 to 2014. However, the U.S. and Europe sales of branded interferon-betas are expected to fall from $4.6 billion in 2010 to $2.4 billion in 2017. The soaring cost of clinical development, the conservative prescribing habits of neurologists, and the expected decline in the use of interferon-betas may induce biosimilar developers to explore other classes of biologics to invest their R&D funds[ data].</center>
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''3'''</center>
| style="padding:0.079cm;"| <center>Interferon gamma</center>
| style="padding:0.079cm;"| <center>The global biosimilar interferon gamma market was $2.2 million 2008 and is expected to reach $141.5 million in 2014 at a CAGR of 94.2% from 2009 to 2014. While the Asian market accounted for the highest share of $0.5 million in 2008, the American market is expected to have the highest CAGR of 107.6% from 2009 to 2014[ data].</center>